Posted on 09 November 2012.
Lundbeck earnings undercut by Lexapro decline
Danish drugmaker Lundbeck, whose Lexapro sales have been depressed by generics, managed to maintain a flat operating profit in its third quarter as it works on a potential new blockbuster in hopes of better days to come. Its operating profit was DKK661 …
Full News here – Read more on FiercePharma